Abstract
The blood–brain barrier (BBB) transport of brain-derived neurotrophic factor (BDNF) in anesthetized rats was examined in the present studies using vector-mediated peptide drug delivery. Following tritiation, the BDNF was biotinylated via a disulfide linker and was coupled to a covalent conjugate of neutral avidin (NLA), which binds the biotinylated peptide with a high affinity, and the murine OX26 monoclonal antibody to the rat transferrin receptor. Owing to the abundance of transferrin receptors on brain capillary endothelium, the OX26 monoclonal antibody undergoes receptor-mediated transcytosis through the BBB, and the NLA–OX26 conjugate transports biotinylated peptide therapeutics through the BBB. The present studies show that while unconjugated BDNF was not transported through the BBB in vivo, the conjugation of biotinylated BDNF to the NLA–OX26 vector resulted in a marked increase in the brain delivery of BDNF, as defined by measurements of the percentage of the injected dose (ID) delivered per gram of brain. Although BDNF was not transported through the BBB in vivo, this cationic peptide was avidly bound by isolated human brain capillaries via a low-affinity, high-capacity system that was inhibited by protamine and by serum protein binding of BDNF. In conclusion, these studies show that the delivery of unconjugated BDNF to brain is nil owing to the combined effects of negligible BBB transport and rapid systemic clearance of intravenous administered BDNF. The brain delivery of BDNF may be augmented by conjugation of BDNF to BBB drug delivery vectors, such as the NLA–OX26 conjugate.
Similar content being viewed by others
REFERENCES
W. C. Mobley, A. C. Server, D. N. Ishii, R. J. Riopelle, and E. M. Shooter. Nerve growth factor. N. Engl. J. Med. 297:1096–1104 (1977).
G. D. Yancopoulos, P. C. Maisonpierre, N. Y. Ip, T. H. Aldrich, L. Belluscio, T. G. Boulton, M. H. Cobb, S. P. Squinto, and M. E. Furth. Neurotrophic factors, their receptors, and the signal transduction pathways they activate. Cold Spring Harbor Symp. Quant. Biol. 55:371–379 (1990).
R. F. Alderson, A. L. Alterman, Y.-A. Barde, and R. M. Lindsay. Brain-derived neurotrophic factor increases survival and differentiated functions of rat septal cholinergic neurons in culture. Neuron 5:297–306 (1990).
B. Knüsel, J. W. Winslow, A. Rosenthal, L. E. Burton, D. P. Seid, K. Nikolics, and F. Hefti. Promotion of central cholinergic and dopaminergic neuron differentiation by brain-derived neurotrophic factor but not neurotrophin 3. Proc. Natl. Acad. Sci. USA 88:961–965 (1991).
C. Hyman, M. Hofer, Y.-A. Barde, M. Juhasz, G. D. Yancopoulos, S. P. Squinto, and R. M. Lindsay. BDNF is a neurotrophic factor for dopaminergic neurons of thesubstantia nigra. Nature 350:320–232 (1991).
M. B. Spina, S. P. Squinto, J. Miller, R. M. Lindsay, and C. Hyman. Brain-derived neurotrophic factor protects dopamine neurons against 6-hydroxydopamine and N-methyl-4-phenylpyridinium ion toxicity: involvement of the glutathione system. J. Neurochem. 59:99–106 (1992).
C. A. Altar, C. B. Boylan, C. Jackson, S. Hershenson, J. Miller, S. J. Wiegand, R. M. Lindsay, and C. Hyman. Brain-derived neurotrophic factor augments rotational behavior and nigrostriatal dopamine turnover in vivo. Proc. Natl. Acad. USA 89:11347–11351 (1992).
M. M. LaVail, K. Unoki, D. Yasumura, M. T. Matthes, G. D. Yancopoulos, and R. H. Steinberg. Multiple growth factors, cytokines, and neurotrophins rescue photoreceptors from the damaging effects of constant light. Proc. Natl. Acad. Sci. USA 89:11249–11253 (1992).
O. Lindvall, P. Ernfors, J. Bengzon, Z. Kokaia, M.-L. Smith, B. K. Siesjö, and H. Persson. Differential regulation of mRNAs for nerve growth factor, brain-derived neurotrophic factor, and neurotrophin 3 in the adult rat brain following cerebral ischemia and hypoglycemic coma. Proc. Natl. Acad. Sci. USA 89:648–652 (1992).
H. S. Phillips, J. M. Hains, G. R. Laramee, A. Rosenthal, and J. W. Winslow. Widespread expression of BDNF but not NT3 by target areas of basal forebrain cholinergic neurons. Science 250:290–294 (1990).
W. M. Pardridge. Peptide Drug Delivery to the Brain, Raven Press, New York, 1991, pp. 1–357.
P. M. Friden, L. R. Walus, P. Watson, S. R. Doctrow, J. W. Kozarich, C. Backman, H. Bergman, B. Hoffer, F. Bloom, and A.-C. Granholm. Blood-brain barrier penetration and in vivo activity of an NGF conjugate. Science 259:373–377 (1993).
T. Yoshikawa and W. M. Pardridge. Biotin delivery to brain with a covalent conjugate of avidin and a monoclonal antibody to the transferrin receptor. J. Pharmacol. Exp. Ther. 263:897–903 (1992).
Y.-S. Kang and W. M. Pardridge. Use of neutral-avidin improves pharmacokinetics and brain delivery of biotin bound to an avidin-monoclonal antibody conjugate. J. Pharmacol. Exp. Ther. 269:344–350 (1994).
W. M. Pardridge, J. L. Buciak, and T. Yoshikawa. Transport of recombinant CD4 through the rat blood-brain barrier. J. Pharmacol. Exp. Ther. 261:1175–1180 (1992).
U. Bickel, T. Yoshikawa, E. M. Landaw, K. F. Faull, and W. M. Pardridge. Pharmacologic effects in vivo in brain by vector-mediated peptide drug delivery. Proc. Natl. Acad. Sci. 90:2618–2622 (1993).
W. M. Pardridge, J. Eisenberg, and J. Yang. Human blood-brain barrier insulin receptor. J. Neurochem. 44:1771–1778 (1985).
M. Gibaldi and D. Perrier. Pharmacokinetics, Marcel Dekker, New York (1982).
J. Leibrock, F. Lottspeich, A. Hohn, M. Hofer, B. Hengerer, P. Masiakowski, H. Thoenen, and Y.-A. Barde. Molecular cloning and expression of brain-derived neurotrophic factor. Nature 341:149–152 (1989).
K. R. Jones and L. F. Reichardt. Molecular cloning of a human gene that is a member of the nerve growth factor family. Proc. Natl. Acad. Sci. USA 87:8060–8064 (1990).
A. Rosenthal, D. V. Goeddel, T. Nguyen, E. Martin, L. E. Burton, A. Shih, G. R. Laramee, F. Wurm, A. Mason, K. Nikolics, and J. W. Winslow. Primary structure and biological activity of human brain-derived neurotrophic factor. Endocrinology 129:1289–1294 (1991).
A. W. Vorbrodt. Ultracytochemical characterization of anionic sites in the wall of brain capillaries. J. Neurocytol. 18:359–368 (1989).
W. M. Pardridge, J. L. Buciak, Y.-S. Kang, and R. J. Boado. Protamine-mediated transport of albumin into brain and other organs in the rat. Binding and endocytosis of protamine-albumin complex by microvascular endothelium. J. Clin. Invest. 92: 2224–2229 (1993).
M. A. Lupo, W. T. Cefalu, and W. M. Pardridge. Kinetics of lactate transport into rat liver in vivo. Metabolism 39:374–378 (1990).
Y.-S. Kang, U. Bickel, and W. M. Pardridge. Pharmacokinetics and saturable blood-brain barrier transport of biotin bound to a conjugate of avidin and a monoclonal antibody to the transferrin receptor. Drug Metabol. Disp. 22:99–105 (1994).
U. Bickel and W. M. Pardridge. Rapid cleavage of disulfide-based chimeric peptides by rat brain in vivo. Faseb J., in press (1994).
M. B. Rosenberg, E. Hawrot, and X. O. Breakefield. Receptor binding activities of biotinylated derivatives of β-nerve growth factor. J. Neurochem. 46:641–648 (1986).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Pardridge, W.M., Kang, YS. & Buciak, J.L. Transport of Human Recombinant Brain-Derived Neurotrophic Factor (BDNF) Through the Rat Blood−Brain Barrier in Vivo Using Vector-Mediated Peptide Drug Delivery. Pharm Res 11, 738–746 (1994). https://doi.org/10.1023/A:1018940732550
Issue Date:
DOI: https://doi.org/10.1023/A:1018940732550